E-ISSN 2250-0944
ISSN 2250-1150
doi: 10.31838/ijprt/16.01.123

Research Article

Contemporary Screening and Evidence-Based Treatment Approaches for Diabetic Retinopathy

Dr. Ibtihaj Imran[1], Dr. Muhammad Farhan Lodhi[2*], Dr. Faisal Anwar[3], Mohammad Younas Khan[4]
[1]MBBS, FCPS Resident, LRBT Free Eye Hospital, Lahore.
[2*]FCPS Opthalmology, FCPS (VRO) fellow L.R.B.T hospital Township Lahore.
[3]Assistant Professor Ophthalmology, Sharif Medical and Dental College / Sharif Medical City Hospital.
[4]Associate Professor Ophthalmology, Islamic International Medical College Trust / Riphah, International Hospital, Islamabad.
Email: [1]ibtihajimran@hotmail.com, [2*]farhanlodhi22@gmail.com, [3]faisal.gemni@gmail.com
Corresponding Author: Mohammad Younas Khan
Received: 07.01.26, Revised: 12.02.26, Accepted: 16.03.26

ABSTRACT
Introduction: Diabetic retinopathy (DR) remains a leading cause of preventable blindness worldwide, resulting from hyperglycemia-induced microvascular damage to the retinal vasculature. The condition is often asymptomatic in early stages, making timely detection crucial.
Objective: This article aims to provide a comprehensive overview of current strategies for screening, diagnosing, and managing diabetic retinopathy, with a focus on evidence-based interventions that reduce disease burden and preserve visual function.
Methods: A systematic review of the literature and critical analysis of clinical guidelines were performed to evaluate diagnostic approaches and therapeutic options, including laser photocoagulation, intravitreal pharmacotherapy, and surgical interventions.
Results: Early detection has been significantly enhanced by modalities such as dilated fundus examinations, high-resolution fundus imaging, and teleophthalmology. Stage-specific interventions—including panretinal photocoagulation, anti-VEGF therapy, and vitrectomy—have proven highly effective in preventing vision loss at various stages of DR.
Conclusion: Comprehensive management integrating systematic screening, early diagnosis, and stageappropriate therapy is essential to reduce both the visual and socioeconomic impact of diabetic retinopathy.

Keywords: Diabetic Retinopathy, Retinal Screening, Laser Photocoagulation, Anti-VEGF Therapy, Fundus Photography, Teleophthalmology, Diabetic Macular Edema, Vision Preservation, Ophthalmic Interventions, Disease Management.

INTRODUCTION

Diabetic retinopathy (DR) is a microvascular complication of diabetes and a leading cause of preventable visual impairment and blindness worldwide [1]. It is estimated that approximately one-third of individuals with diabetes will develop some form of DR during their lifetime. Early stages of the disease are often asymptomatic, making proactive screening essential [2]. The pathophysiology of DR involves chronic hyperglycemia–induced endothelial damage in retinal capillaries, thickening of the basement membrane, pericyte loss, microaneurysm formation, and disruption of the blood-retinal barrier [3].



This cascade can result in ischemia, neovascularization, fibrovascular proliferation, and retinal detachment in advanced stages [4]. Diabetic retinopathy is typically classified into

non-proliferative (NPDR) and proliferative (PDR) forms. NPDR represents the early stage, characterized by microaneurysms, dot and blot hemorrhages, and cotton wool spots [5]. PDR is more severe and involves pathological neovascularization, vitreous hemorrhage, and tractional retinal detachment, often causing sudden and irreversible vision loss [6]. A less common but serious manifestation is diabetic macular edema (DME), which may develop at any stage of retinopathy. DME arises from increased vascular permeability, leading to fluid accumulation in the macula, the retinal region responsible for central vision, and is a major contributor to visual disability in diabetic patients [7]. Early detection is critical, as estimates suggest that up to 90% of DR-related blindness can be prevented through timely screening and intervention [8]. Screening strategies range from dilated fundus examinations to high-resolution fundus imaging and teleophthalmology-based approaches.



Telemedicine integration has proven particularly valuable in resource-limited and rural areas where access to ophthalmologists is limited [9]. Treatment strategies depend on the stage and severity of the disease.

Panretinal photocoagulation (PRP) has remained the cornerstone for managing PDR for decades [10].

Anti-vascular endothelial growth factor (anti-VEGF) therapy has transformed the treatment of DME and PDR, significantly improving visual outcomes [11]. In advanced cases involving non-clearing vitreous hemorrhage or tractional retinal detachment, pars plana vitrectomy offers a surgical option to restore retinal anatomy and halt further progression.

METHODOLOGY

A comprehensive literature review was conducted using PubMed, Cochrane Library, and Scopus databases covering the period from 2010 to 2025. Search terms included "diabetic retinopathy," "screening," "fundus photography," "laser photocoagulation," "anti-VEGF," and "teleophthalmology." Clinical guidelines from the American Diabetes Association (ADA) and the American Academy of Ophthalmology (AAO) were reviewed to ensure adherence to current evidence-based practices. Inclusion criteria comprised guideline recommendations, large cohort studies, meta-analyses, and randomized controlled trials involving type 1 or type 2 diabetic adults. Extracted data included screening sensitivity and specificity, efficacy of interventions, visual acuity outcomes, and rates of disease progression.

Findings were synthesized narratively and summarized in tables for practical clinical application.

RESULTS

Early detection and timely management of diabetic retinopathy are essential for preventing vision loss.

Screening methods, from traditional dilated fundus examinations to advanced imaging technologies, allow accurate diagnosis. Interventions such as laser photocoagulation, anti-VEGF injections, and vitrectomy substantially reduce visual morbidity and help preserve vision when appropriately applied.

Table 1. Comparative Performance of Screening Modalities for Diabetic Retinopathy

Screening Method	Sensitivity (%)	Specificity (%)	Advantages	Limitations

Dilated fundus examination	85–90	85–90	Rapid access, relatively low cost	Requires trained staff, subjective variation
Fundus photography	80–88	84–90	Permanent documentation, allows follow-up	Equipment cost, image quality varies
Optical coherence tomography (OCT)	90–95	90–95	Detects macular edema, high-resolution imaging	High cost, limited rural availability
Teleophthalmology	85–90	80–88	Expands coverage to underserved populations	Internet-dependent infrastructure

Table 2. Current Therapeutic Approaches to Diabetic Retinopathy Treatment Modality Indication

Efficacy	Advantages	Limitations	Treatment Modality	Indication	Efficacy
Advantages					
Panretinal photocoagulation (PRP)	Proliferative diabetic retinopathy (PDR)	Reduces risk of severe visual loss by 50–60%	Proven long-term efficacy	Possible peripheral visual field loss	
Focal/Grid laser	Clinically significant diabetic macular edema (DME)	Stabilizes visual acuity in most patients	Useful adjunct to anti-VEGF therapy	Less vision gain than anti-VEGF	
Anti-VEGF injections	DME and PDR	Visual gain in 30– 40% of patients	Effective, minimally invasive	Requires repeated injections, costly	
Vitrectomy	Non-clearing vitreous hemorrhage, tractional retinal detachment	Restores anatomy, improves vision	Effective for advanced disease	Invasive, requires surgical expertise	

DISCUSSION

Diabetic retinopathy management is a multi-modal process involving early diagnosis, timely intervention, and systemic disease control [12]. Prevention is screen-driven. Dilated fundus examination is costeffective and viable based on the availability of specialists. Digital fundus photography offers objective records and is extensively used in teleophthalmology programs, which are highly effective in extending coverage in underserved areas [13].

Therapeutically, PRP remains a mainstay for proliferative disease with a 50–60% reduction in severe visual impairment [14]. Side effects such as peripheral field limitation require patient-specific decision-making. Anti-VEGF therapy—Ranibizumab, Aflibercept, and Bevacizumab—has revolutionized prognosis in DME and PDR, offering better visual outcomes than laser therapy alone [15]. Challenges remain, including the need for repeated injections and cost considerations, especially in

low-resource settings. Vitrectomy is warranted in late presentations, such as non-clearing vitreous hemorrhage or tractional retinal detachment [16]. Preoperative anti-VEGF treatment can improve surgical outcomes by reducing intraoperative hemorrhage and postoperative complications. Despite these advancements, real-life clinical implementation is suboptimal. Major challenges include poor follow-up, late presentation, and low-coverage screening [17]. Early diagnosis can be improved through routine DR screening as part of diabetes care, education of non-ophthalmic health workers, and AI-based computerized screening [18]. Future therapeutic approaches include sustained-release anti-VEGF devices, neuroprotective agents, and gene therapy for early vascular alterations.

CONCLUSION

Early identification and treatment of diabetic retinopathy can prevent blindness. A systematic approach to routine screening, accurate diagnosis, and evidence-based, stage-specific treatment can significantly reduce blindness rates. Additional applications of teleophthalmology, high-technology imaging, and novel pharmacologic agents increase access and efficacy. Shared care by diabetologists, ophthalmologists, and general practitioners, along with patient education, is critical to maintain vision and enhance quality of life in diabetic patients.

REFERENCES

1. Tripathi, A., Gaur, S., Agarwal, R., Singh, N., Singh, A., Parveen, S., ... & Rima, N. (2025). Disorganization of retinal inner layers as an optical coherence tomography biomarker in diabetic retinopathy: A study. *Indian Journal of Ophthalmology*, 73(9), 1245-1250.
2. Omar, A., Williams, R. G., Whelan, J., Noble, J., Brent, M. H., Giunta, M., ... & Lhor, M. (2024). Diabetic disease of the eye in Canada: consensus statements from a retina specialist working group. *Ophthalmology and Therapy*, 13(5), 1071-1102.
3. Rahat, S. R. U. I., Rahman, M. H., Arafat, Y., Rahaman, M., Hasan, M. M., & Al Amin, M. (2025). Advancing diabetic retinopathy detection with AI and deep learning: Opportunities, limitations, and clinical barriers. *British Journal of Nursing Studies*, 5(2), 01-13.
4. Rák, T., Kovács-Valasek, A., Pöstyéni, E., Gábriel, R., & Csutak, A. (2025). Low vision rehabilitation and eye exercises: A comprehensive guide to tertiary prevention of diabetic retinopathy. *Life*, 15(6), 857.
5. Baiju, B. V., Jain, D., Mehta, D. A., Thakur, S., & Jha, A. R. (2024, October). Predicting diabetic retinopathy with machine learning: Disentangling the diabetes-ocular health complex. In *2024 International Conference on Intelligent Systems and Advanced Applications (ICISAA)* (pp. 1-5). IEEE.
6. Wang, M. H., Xing, L., Pan, Y., Gu, F., Fang, J., Yu, X., ... & Liu, W. (2024). AI-based advanced approaches and dry eye disease detection based on multi-source evidence: Cases, applications, issues, and future directions. *Big Data Mining and Analytics*, 7(2), 445-484.
7. Hodges, B., Shahid, M. M., Qin, H., Omoruyi, F. O., Lyngdoh, J., Patel, D., & Allison, K. (2024). Evaluating the incidence of glaucoma, age-related macular degeneration, and diabetic retinopathy in Western New York and assessing the feasibility of utilizing optical coherence tomography and artificial intelligence for timely identification of these ocular diseases. *J. Community Med. Public Health*, 8, 453.
8. Šulak, M., Jevnikar, K., Drnovšek, F., Vrhovec, L., Urbančič, M., Potrč, M., ... & Petrovič, M. G.
9. (2025). A stepwise implementation of the Slovenian National Diabetic Retinopathy Screening Program–evaluation of the first 4.5 years. *European Journal of Ophthalmology*, 35(2), 660-668.
10. Julius, A., Malakondaiah, S., Subbarayalu, R., & Pothireddy, R. B. (2025). Role of preoperative and postoperative intravitreal anti-VEGF agents in managing diabetic macular edema and diabetic retinopathy. *SN Comprehensive Clinical Medicine*, 7(1), 175.
11. Melo, G. B., Malerbi, F. K., de Medeiros, J. N., & Grauslund, J. (2024). A comprehensive strategy of diabetic retinopathy screening in a public health system: identifying and overcoming obstacles for implementation. *Diabetes Epidemiology and Management*, 13, 100192.
12. Rosenfeld, R. M., Grega, M. L., Karlsen, M. C., Abu Dabrh, A. M., Aurora, R. N., Bonnet, J. P., ... & Gulati, M. (2025). Lifestyle interventions for treatment and remission of type 2 diabetes and

prediabetes in adults: a clinical practice guideline from the American College of Lifestyle Medicine. *American Journal of Lifestyle Medicine*, 19(2_suppl), 10S-131S.

13. Radke, N. V., Ruamviboonsuk, P., Steel, D. H., Tian, T., Hunyor, A. P., Tsai, A. S., ... & Lam, D. S. (2025). Controversies, consensuses, and guidelines on macular hole surgery by the Asia–Pacific Vitreo-retina Society (APVRS) and the Asia–Pacific Academy of Professors in Ophthalmology (AAPPO). *Eye and Vision*, 12(1), 30.
14. Alomari, O., Mokresh, M. E., Hamam, M., Teker, A. U., Caliskan, C. S., Sadigova, S., ... & Filinte, G. (2025). Combined stromal vascular fraction and fractional CO2 laser therapy for hypertrophic scar treatment: a systematic study and meta-analysis. *Aesthetic Plastic Surgery*, 49(3), 885-896.
15. Karabeg, M., Petrovski, G., Holen, K., Steffensen Sauesund, E., Fosmark, D. S., Russell, G., ... & Petrovski, B. E. (2025). Comparison of validity and reliability of manual consensus grading vs. automated AI grading for diabetic retinopathy screening in Oslo, Norway: A cross-sectional pilot study. *Journal of Clinical Medicine*, 14(13), 4810.
16. Carrillo-Larco, R. M., Bravo-Rocca, G., Castillo-Cara, M., Xu, X., & Bernabe-Ortiz, A. (2024). A multimodal approach using fundus images and text meta-data in a machine learning classifier with embeddings to predict years with self-reported diabetes–An exploratory analysis. *Primary Care Diabetes*, 18(3), 327-332.
17. Santos, L. F., Sánchez-Tena, M. Á., Alvarez-Peregrina, C., Sánchez-González, J. M., & MartinezPerez, C. (2025). The role of artificial intelligence in optometric diagnostics and research: Deep learning and time-series forecasting applications. *Technologies*, 13(2), 77.
18. Lockhart, C. M., Barakat, M. R., Dunn, J. D., Richardson, T., Bratcher, T., Greene, E., ... & Wigginton, J. (2025). Transforming retinal disease management through diabetes care: AMCP Market Insights: Chief Medical and Pharmacy Officers Summit. *Journal of Managed Care & Specialty Pharmacy*, 31(4-a Suppl), S1-S11.
19. Fickweiler, W., Sampani, K., Markel, D. S., Levine, S. R., Sun, J. K., & Gardner, T. W. (2025).
20. Advancing toward a world without vision loss from diabetes: Insights from the Mary Tyler Moore Vision Initiative Symposium 2024 on curing vision loss from diabetes. *Translational Vision Science & Technology*, 14(5), 12-12.